{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T13:18:36Z","timestamp":1777987116745,"version":"3.51.4"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Burn patients have a higher chance of developing thromboembolic complications, leading to worsened mortality rates, so prophylactic anticoagulation is important. Anticoagulants such as enoxaparin, a low-molecular-weight heparin, and unfractionated heparin (UFH) have been frequently used as chemical prophylactic treatments of thromboembolism. Enoxaparin has been shown to have lower mortality and higher efficacy in surgical patients and coronary artery disease patients. The aim of the study is to assess mortality and compare the safety of enoxaparin and heparin in acute burn patients. A retrospective cohort study of 26,572 burn patients was conducted using the TriNetX database. Patients were divided into 2 cohorts: those receiving only UFH (Cohort 1) and those receiving only enoxaparin (Cohort 2) prophylaxis within 24 hours after burn injury. Cohorts were matched with 1:1 propensity score matching to correct for differences in age, gender, ethnicity, race, burn severity, inhalation injury, diabetes mellitus, acute myocardial infarction, stroke, and central line venous catheter placement. Outcomes assessed included mortality and deep vein thrombosis within a month (30 days). After matching, the enoxaparin (n = 7,484) cohort showed significantly lower 30-day mortality (1.3%) compared to the UFH (n = 7,484) cohort (3.6%) (risk ratio [RR] = 2.70, 95% CI: 2.15-3.40, P &amp;lt; .05). Kaplan-Meier analysis demonstrated a higher survival probability in the enoxaparin group (98.6% vs 96.4%, P &amp;lt; .05). DVT risk was slightly higher with UFH but not statistically significant (RR = 1.18, 95% CI: 0.54-2.54, P = .68). Prophylactic anticoagulation with enoxaparin is associated with a significant lower 30-day mortality risk compared to UFH.<\/jats:p>","DOI":"10.1093\/jbcr\/iraf080","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T08:06:16Z","timestamp":1746259576000},"page":"773-779","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Heparin and Enoxaparin Anticoagulant Prophylaxis on Improving Acute Mortality in Burn Patients"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3259-3349","authenticated-orcid":false,"given":"Manav M","family":"Patel","sequence":"first","affiliation":[{"name":"John Sealy School of Medicine, University of Texas Medical Branch , Galveston, TX ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4334-5475","authenticated-orcid":false,"given":"Shawn E","family":"Lim","sequence":"additional","affiliation":[{"name":"John Sealy School of Medicine, University of Texas Medical Branch , Galveston, TX ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1424-2754","authenticated-orcid":false,"given":"Victoria A","family":"Cuello","sequence":"additional","affiliation":[{"name":"John Sealy School of Medicine, University of Texas Medical Branch , Galveston, TX ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4785-2011","authenticated-orcid":false,"given":"Joshua E","family":"Lewis","sequence":"additional","affiliation":[{"name":"John Sealy School of Medicine, University of Texas Medical Branch , Galveston, TX ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3657-0633","authenticated-orcid":false,"given":"Amina","family":"El Ayadi","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Texas Medical Branch , Galveston, TX ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J","family":"Erickson","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Texas Medical Branch , Galveston, TX ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2972-3440","authenticated-orcid":false,"given":"Steven E","family":"Wolf","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Texas Medical Branch , Galveston, TX ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9371-9078","authenticated-orcid":false,"given":"Juquan","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Texas Medical Branch , Galveston, TX ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"2026050508223068200_ref1","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/SHK.0000000000001484","article-title":"Burn-induced coagulopathies: a comprehensive review","volume":"54","author":"Ball","year":"2020","journal-title":"Shock (Augusta, Ga.)"},{"key":"2026050508223068200_ref2","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.bjps.2020.12.011","article-title":"Venous thromboembolism in burns patients: are we underestimating the risk and underdosing our prophylaxis?","volume":"74","author":"Lu","year":"2021","journal-title":"J Plastic Reconst Aesthetic Sur"},{"key":"2026050508223068200_ref3","article-title":"Virchow triad.","volume-title":"StatPearls","author":"Kushner","year":"2024"},{"key":"2026050508223068200_ref4","author":"Virchow\u2019s Legacy: Deep Vein Thrombosis and Pulmonary Embolism - PubMed"},{"key":"2026050508223068200_ref5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1055\/s-0033-1351130","article-title":"Venous thromboembolism prophylaxis","volume":"26","author":"Laryea","year":"2013","journal-title":"Clin Colon Rectal Surg"},{"key":"2026050508223068200_ref6","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3390\/medicina60020258","article-title":"Venous thromboembolism in burn patients: a 5-year retrospective study","volume":"60","author":"Bordeanu-Diaconescu","year":"2024","journal-title":"Medicina (Kaunas, Lithuania)"},{"key":"2026050508223068200_ref7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s11239-022-02755-w","article-title":"Enoxaparin may be associated with lower rates of mortality than unfractionated heparin in neurocritical and surgical patients","volume":"55","author":"Samuel","year":"2023","journal-title":"J Thromb Thrombolysis"},{"key":"2026050508223068200_ref8","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1136\/bmj.e553","article-title":"Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis","volume":"344","author":"Silvain","year":"2012","journal-title":"BMJ (Clin Res)"},{"key":"2026050508223068200_ref9","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/S0140-6736(07)60633-3","article-title":"The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison","volume":"369","author":"Sherman","year":"2007","journal-title":"Lancet (London, England)"},{"key":"2026050508223068200_ref10","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1097\/TA.0000000000000750","article-title":"Heparin versus enoxaparin for prevention of venous thromboembolism after trauma: a randomized noninferiority trial","volume":"79","author":"Olson","year":"2015","journal-title":"J Trauma Acute Care Surg"},{"key":"2026050508223068200_ref11","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/phar.2518","article-title":"Enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in renally impaired ICU patients","volume":"41","author":"DeBiase","year":"2021","journal-title":"Pharmacotherapy"},{"key":"2026050508223068200_ref12","article-title":"Heparin-induced thrombocytopenia.","volume-title":"StatPearls","author":"Nicolas","year":"2025"},{"key":"2026050508223068200_ref13","article-title":"Low-Molecular-Weight Heparin (LMWH).","volume-title":"StatPearls","author":"Patel","year":"2025"},{"key":"2026050508223068200_ref14","doi-asserted-by":"publisher","DOI":"10.18103\/mra.v11i6.3960","article-title":"Optimizing prophylactic anticoagulation in burns is associated with low incidence of venous thromboembolic complications","volume":"11","author":"Mokline","year":"2023","journal-title":"Med Res Arch"},{"key":"2026050508223068200_ref15","article-title":"30 above and beyond: enoxaparin dose adjustment is required for adequate VTE prophylaxis in burn patients","journal-title":"J Burn Care Res."},{"key":"2026050508223068200_ref16","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.burns.2019.02.011","article-title":"Anti-Xa guided enoxaparin dose adjustment improves pharmacologic deep venous thrombosis prophylaxis in burn patients","volume":"45","author":"Cronin","year":"2019","journal-title":"Burns"},{"key":"2026050508223068200_ref17","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1097\/BCR.0b013e31822dc3c7","article-title":"Clinically significant venous thromboembolic complications in burn patients receiving unfractionated heparin or enoxaparin as prophylaxis","volume":"32","author":"Bushwitz","year":"2011","journal-title":"J Burn Care Res"},{"key":"2026050508223068200_ref18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1055\/s-0038-1650617","article-title":"A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group","volume":"76","author":"Bergmann","year":"1996","journal-title":"Thromb Haemost"},{"key":"2026050508223068200_ref19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.6001\/actamedica.v26i1.3954","article-title":"Prophylactic anti-coagulation after severe burn injury in critical care settings","volume":"26","author":"Blake","year":"2019","journal-title":"Acta Med Litu"},{"key":"2026050508223068200_ref20","article-title":"Heparin.","volume-title":"StatPearls","author":"Warnock","year":"2025"},{"key":"2026050508223068200_ref21","article-title":"Enoxaparin.","volume-title":"StatPearls","author":"Jupalli","year":"2025"},{"key":"2026050508223068200_ref22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4103\/0972-5229.99107","article-title":"Low molecular weight heparin in prophylaxis of deep vein thrombosis in Asian general surgical patients: a Kashmir experience","volume":"16","author":"Dar","year":"2012","journal-title":"Indian J Crit Care Med"},{"key":"2026050508223068200_ref23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11239-015-1314-3","article-title":"Pharmacology of anticoagulants used in the treatment of venous thromboembolism","volume":"41","author":"Nutescu","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"2026050508223068200_ref24","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.2165\/00003088-200342120-00003","article-title":"Pharmacodynamic and pharmacokinetic properties of enoxaparin: implications for clinical practice","volume":"42","author":"Fareed","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"2026050508223068200_ref25","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1001\/archinte.161.16.1952","article-title":"Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review","volume":"161","author":"Hull","year":"2001","journal-title":"Arch Intern Med"},{"key":"2026050508223068200_ref26","doi-asserted-by":"publisher","first-page":"1179545X198638141179545X19863814","DOI":"10.1177\/1179545X19863814","article-title":"Enoxaparin dosing for venous thromboembolism prophylaxis in low body weight patients","volume":"12","author":"Dybdahl","year":"2019","journal-title":"Clin Med Insights Blood Disord"}],"container-title":["Journal of Burn Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbcr\/advance-article-pdf\/doi\/10.1093\/jbcr\/iraf080\/63158653\/iraf080.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbcr\/article-pdf\/47\/3\/773\/63158653\/iraf080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbcr\/article-pdf\/47\/3\/773\/63158653\/iraf080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:22:39Z","timestamp":1777983759000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbcr\/article\/47\/3\/773\/8129058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,5,13]]},"published-print":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jbcr\/iraf080","relation":{},"ISSN":["1559-047X","1559-0488"],"issn-type":[{"value":"1559-047X","type":"print"},{"value":"1559-0488","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2025,5,13]]}}}